A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib

Menglin Guo\textsuperscript{1,2}, Yamin Shu\textsuperscript{1,2}, Guosong Chen\textsuperscript{1}, Juan Li\textsuperscript{*1} & Feie Li\textsuperscript{*1}

Niraparib was approved for the treatment of platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube and primary peritoneal cancer. The authors retrospectively investigated niraparib-related adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Four algorithms were employed to quantify the signals of niraparib associated AEs, using data from the FAERS between 2017 and 2021. MYSQL 8.0, Navicat Premium 15, Microsoft EXCEL 2019 and the GraphPad Prism 8 were used to conduct statistical analysis. There are 7,238,157 reports collected from the FAERS database, of which 11,701 reports listed niraparib as the ‘primary suspected (PS)’ drug. A total of 97 significant disproportionality PTs conforming to the four algorithms were simultaneously retained. Unexpected significant AEs such as neuropathy peripheral, photosensitivity reaction, gastrooesophageal reflux disease might also occur. The median onset time of niraparib-associated AEs was 18 days (interquartile range [IQR] 4–66 days), and most of the cases occurred within the first months after niraparib initiation. The study found niraparib-associated AEs and might provide important support for clinical monitoring and risk identification of niraparib.

Niraparib is a potent and highly selective inhibitor of poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) 1/2 that play a role in DNA repair\textsuperscript{1,2}. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cell death\textsuperscript{3}. Niraparib was approved in the United States Food and Drug Administration (FDA) in March 2017. Maintenance therapy with niraparib can lengthen progression-free survival and the chemotherapy-free interval for adult patients with platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube or primary peritoneal cancer\textsuperscript{4–6}. Better understanding of the real-world safety profile of niraparib in patients with ovarian cancer will lead to better compliance, decrease interruptions, and reflect on the desirable progression-free survival and overall survival.

In the clinical phase II and phase III studies of niraparib, the most common treatment-emergent adverse drug reactions (ADRs) included hematological toxicity (white blood cell count decreased, neutrophil count decreased, platelet count decreased, anemia and so on), fatigue, insomnia, hypertension, constipation, nausea, vomiting and diarrhea, which were manageable in the clinical trial setting\textsuperscript{7–9}. A study in patients with recurrent ovarian cancer treated with niraparib showed that niraparib was well tolerated, with 14.7% of patients discontinuing treatment due to treatment-emergent adverse events (TEAEs)\textsuperscript{10}. The long-term efficacy and safety data of niraparib have only been reported in case reports or clinical trials, and ADRs are mainly focused on a single or several systems due to relatively small sample sizes, selection criteria and limited duration of follow-ups. Currently, data on the large sample and real-world comprehensive safety of niraparib are lacking. Niraparib is the most representative PARP inhibitor in the maintenance therapy of platinum-sensitive advanced/recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, and has been widely used in clinic\textsuperscript{11}. With the wide use of niraparib in clinical practice, and scarcity in evaluations of the adverse events (AEs) in real-world cohorts, we conducted this pharmacovigilance analysis to evaluate the safety profile of niraparib. Therefore, it is very necessary to use data mining algorithm to search for the potential ADRs signals of niraparib by post-marketing monitoring.

FAERS is the FDA Adverse Event Reporting System, which is a public, voluntary, spontaneous reporting database and a post-marketing repository for AE reports, product quality complaints, and medication error reports.

\textsuperscript{1}Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430030, China. \textsuperscript{2}These authors contributed equally: Menglin Guo and Yamin Shu. \textsuperscript{*}Email: lijuan@tjh.tjmu.edu.cn; lifeie@tjh.tjmu.edu.cn
related to any FDA-approved therapy.12,13 Manufacturers are required to send any AE reports to the FDA, while global healthcare professionals and consumers may voluntarily do so. The spontaneous reporting system has been utilized in pharmacovigilance for safety assessment of suspected AEs and plays a major part in signal identification due to inherent limitations of clinical trials such as stringent trial design, strict enrollment criteria, relatively small sample size and limited follow-up duration.11 In this study, we evaluated the AE reports of niraparib, and aimed to assess the potential relevance between niraparib and AE reports through data mining of FAERS.

Results

Descriptive analysis. During the study period, a total of 7,238,157 eligible cases were identified from the quarterly files from FAERS. There were 11,701 case reports of niraparib as the PS and 82,871 AEs were found to be related to niraparib. The clinical characteristics of events with niraparib are described in Table 1. Among all AEs, females (78.55%) accounted for a larger proportion than males (1.79%). In terms of age composition, patients were mainly aged ≥ 40 years old. Ovarian cancer was the most reported indication (70.61%), followed by fallopian tube cancer (4.86%), malignant peritoneal neoplasm (4.54%) and uterine cancer (1.28%). Death or life-threatening events were reported in 771 (6.59%) and 592 (5.06%) cases, respectively. In addition to other serious

| Characteristics                  | Case number, n | Case proportion, % |
|----------------------------------|----------------|-------------------|
| Number of events                 | 11,701         |                   |
| Sex                              |                |                   |
| Female                           | 9191           | 78.55             |
| Male                             | 209            | 1.79              |
| Unknown                          | 2301           | 19.66             |
| Age                              |                |                   |
| <40                              | 58             | 0.50              |
| 40–50                            | 253            | 2.16              |
| >50                              | 3925           | 33.54             |
| Unknown or missing               | 7465           | 63.80             |
| Indications (Top four)           |                |                   |
| Ovarian cancer                   | 8262           | 70.61             |
| Fallopian tube cancer            | 569            | 4.86              |
| Malignant peritoneal neoplasm    | 531            | 4.54              |
| Uterine cancer                   | 150            | 1.28              |
| Serious outcome                  |                |                   |
| Death                            | 771            | 6.59              |
| Disability                       | 30             | 0.26              |
| Hospitalization-initial or prolonged | 2614         | 22.34             |
| Life-threatening                  | 592            | 5.06              |
| Other serious medical events     | 5461           | 46.67             |
| Reported countries (Top five)    |                |                   |
| America                          | 10,214         | 87.29             |
| Japan                            | 282            | 2.41              |
| Canada                           | 214            | 1.83              |
| France                           | 184            | 1.57              |
| Great Britain                    | 167            | 1.43              |
| Reported person                  |                |                   |
| Consumer                         | 9060           | 77.43             |
| Health professional              | 184            | 1.57              |
| Lawyer                           | 2              | 0.02              |
| Physician                        | 1634           | 13.96             |
| Other health-professional        | 445            | 3.80              |
| Pharmacist                       | 122            | 1.04              |
| Reporting year                   |                |                   |
| 2017                             | 931            | 7.96              |
| 2018                             | 3169           | 27.08             |
| 2019                             | 1379           | 11.79             |
| 2020                             | 2370           | 20.25             |
| 2021                             | 3852           | 32.92             |

Table 1. Clinical characteristics of reports with niraparib from the FAERS database (2017 to 2021).
### Table 2. Signal strength of reports of niraparib at the System Organ Class (SOC) level in FAERS database.

*Indicates statistically significant signals in algorithm. ROR: reporting odds ratio; CI: confidence interval; PRR: proportional reporting ratio; χ²: chi-squared; IC: information component; IC025: the lower limit of 95% CI of the IC; EBM: empirical Bayesian geometric mean; EBM05: the lower limit of 95% CI of EBM.

| System organ class (SOC) | Niraparib cases reporting SOC | ROR (95% two-side CI) | PRR (χ²) | IC (IC025) | EBM (EBM05) |
|--------------------------|--------------------------------|-----------------------|---------|-----------|-------------|
| General disorders and administration site conditions | 6849 | 2.23 (2.15–2.31)* | 1.51 (1919.11) | 0.59 (0.55) | 1.51 (1.45) |
| Investigations | 6136 | 8.52 (8.21–8.83)* | 4.58 (19236.96) * | 2.18 (1.24) | 4.55 (4.39) * |
| Gastrointestinal disorders | 6100 | 4.93 (4.76–5.11)* | 2.88 (9118.11) | 1.52 (1.40) | 2.87 (2.77) * |
| Nervous system disorders | 4681 | 2.54 (2.45–2.64)* | 1.93 (2623.36) * | 0.94 (0.89) | 1.92 (1.85) |
| Injury, poisoning and procedural complications | 4303 | 1.40 (1.35–1.46)* | 1.25 (312.76) | 0.33 (0.28) | 1.25 (1.21) |
| Psychiatric disorders | 3466 | 2.82 (2.71–2.93)* | 2.28 (2855.85) | 1.19 (1.13) | 2.28 (2.19) * |
| Vascular disorders | 3023 | 1.96 (1.88–2.04)* | 1.71 (1044.53) * | 0.77 (0.71) | 1.71 (1.64) |
| Cardiac disorders | 2679 | 2.37 (2.27–2.47)* | 2.05 (1623.36) | 1.03 (0.97) | 2.05 (1.96) |
| Respiratory, thoracic and mediastinal disorders | 2675 | 1.77 (1.69–1.85)* | 1.59 (687.24) | 0.67 (0.61) | 1.59 (1.52) |
| Musculoskeletal and connective tissue disorders | 2557 | 1.56 (1.49–1.63)* | 1.42 (1049.19) | 0.77 (0.71) | 1.42 (1.36) |
| Skin and subcutaneous tissue disorders | 2343 | 1.29 (1.23–1.35)* | 1.23 (215.87) | 0.33 (0.28) | 1.23 (1.18) |
| Metabolism and nutrition disorders | 1999 | 2.69 (2.56–2.82)* | 2.4 (1750.42) | 1.26 (1.19) | 2.4 (2.30) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1941 | 3.81 (3.63–4.00)* | 3.34 (3430.09) | 1.73 (1.60) | 3.34 (3.17) |
| Infections and infestations | 1543 | 1.25 (1.18–1.32)* | 1.21 (67.50) | 0.28 (0.20) | 1.21 (1.15) |
| Surgical and medical procedures | 1271 | 3.54 (3.34–3.75)* | 3.26 (2053.40) | 1.70 (1.61) | 3.25 (3.07) |
| Renal and urinary disorders | 1262 | 1.60 (1.51–1.70)* | 1.54 (255.62) | 0.62 (0.53) | 1.54 (1.45) |
| Reproductive system and breast disorders | 123 | 1.31 (1.21–1.41)* | 1.29 (46.14) | 0.36 (0.25) | 1.29 (1.19) |
| Eye disorders | 551 | 1.11 (1.02–1.21)* | 1.10 (5.53) | 0.14 (0.01) | 1.10 (1.01) |
| Immune system disorders | 500 | 0.41 (0.38–0.45) | 0.44 (397.38) | −1.19 (−1.32) | 0.44 (0.40) |
| Hepatobiliary disorders | 425 | 1.36 (1.23–1.49)* | 1.34 (38.12) | 0.42 (0.28) | 1.34 (1.22) |
| Social circumstances | 287 | 2.08 (1.85–2.33)* | 2.05 (155.59) | 1.02 (0.85) | 2.05 (1.82) |
| Ear and labyrinth disorders | 212 | 1.42 (1.24–1.62) | 1.41 (25.58) | 0.49 (0.29) | 1.41 (1.23) |
| Endocrine disorders | 171 | 0.55 (0.48–0.64) | 0.56 (60.68) | −0.84 (−1.06) | 0.56 (0.48) |
| Product issues | 91 | 0.18 (0.14–0.22) | 0.18 (347.20) | −2.45 (−2.76) | 0.18 (0.15) |
| Congenital, familial and genetic disorders | 19 | 0.28 (0.18–0.43) | 0.28 (35.93) | −1.87 (−2.53) | 0.28 (0.18) |
| Pregnancy, puerperium and perinatal conditions | 13 | 0.06 (0.03–0.10) | 0.06 (192.62) | −4.05 (−4.85) | 0.06 (0.04) |

### Signal of system organ class.

Signal strengths of reports of niraparib at the System Organ Class (SOC) level are described in Table 2. Statistically, we found that niraparib-induced AEs occurrence targeted 27 organ systems. The significant SOCs that at least one of the four indices met the criteria were general disorders and administration site conditions (SOC: 10018065, 6849), investigations (SOC: 10022891, 6136), gastrointestinal disorders (SOC: 10017947, 6100), nervous system disorders (SOC: 10029205, 4681), injury, poisoning and procedural complications (SOC: 10022117, 4303).

### Signal of preferred terms.

We further examined PT signals, a total of 97 significant disproportionality PTs conforming to the four algorithms simultaneously (Table 3). Blood and lymphatic system events, gastrointestinal events, cardiovascular events, and nervous system events that are included in the label are usually reported in patients with niraparib. In this study, fatigue (PT: 10016256), nausea (PT: 10028813), vomiting (PT: 10047700), constipation (PT: 10010774), anaemia (PT: 10002034), thrombocytopenia (PT: 10043554), headache (PT: 10019211), hypertension (PT: 1002772), insomnia (PT: 10022437) have been reported in patients with niraparib. In this study, fatigue (PT: 10016256), nausea (PT: 10028813), vomiting (PT: 10047700), constipation (PT: 10010774), anaemia (PT: 10002034), thrombocytopenia (PT: 10043554), headache (PT: 10019211), hypertension (PT: 1002772), insomnia (PT: 10022437) have been reported in patients with niraparib. In this study, fatigue (PT: 10016256), nausea (PT: 10028813), vomiting (PT: 10047700), constipation (PT: 10010774), anaemia (PT: 10002034), thrombocytopenia (PT: 10043554), headache (PT: 10019211), hypertension (PT: 1002772), insomnia (PT: 10022437) have been reported in patients with niraparib.
### Preferred terms (PTs)

| SOC                                      | Prefered terms (PTs) | Niraparib cases reporting PT | ROR (95% two-sided CI) | PRR ($\chi^2$) | IC (IC0.25) | EBGM (EBGM05) |
|------------------------------------------|----------------------|-----------------------------|------------------------|----------------|--------------|---------------|
| Blood and lymphatic system disorders     |                      |                             |                        |                |              |               |
| Anaemia                                  | 772                  |                             | 8.52 (7.94–9.17)       | 8.02 (4723.29) | 2.97 (2.87) | 7.93 (7.37)   |
| Thrombocytopenia                         | 606                  |                             | 11.02 (10.15–11.97)    | 10.50 (5148.09)| 3.35 (3.22) | 10.34 (9.52)  |
| Lymphadenopathy                          | 127                  |                             | 7.18 (6.02–8.56)       | 7.11 (660.38)  | 2.74 (2.48) | 7.04 (5.91)   |
| Pancytopenia                             | 124                  |                             | 4.53 (3.80–5.42)       | 4.50 (335.57)  | 2.11 (1.85) | 4.47 (3.74)   |
| Cardiac disorders                        |                      |                             |                        |                |              |               |
| Palpitations                             | 361                  |                             | 6.21 (5.59–6.90)       | 6.05 (1514.14) | 2.56 (2.41) | 6.00 (5.40)   |
| Tachycardia                              | 121                  |                             | 2.58 (2.15–3.08)       | 2.56 (115.10)  | 1.32 (1.06) | 2.55 (2.13)   |
| Gastrointestinal disorders               |                      |                             |                        |                |              |               |
| Anaemia                                  | 772                  |                             | 8.52 (7.94–9.17)       | 8.02 (4723.29) | 2.97 (2.87) | 7.93 (7.37)   |
| Nausea                                   | 3459                 |                             | 11.59 (11.14–12.06)    | 8.46 (23269.91)| 3.06 (3.00) | 8.36 (8.03)   |
| Constipation                             | 2499                 |                             | 27.71 (26.50–28.99)    | 22.03 (48882.17)| 4.40 (4.34) | 21.29 (20.35) |
| Vomiting                                 | 1245                 |                             | 5.79 (5.46–6.14)       | 5.28 (4374.92) | 2.39 (2.30) | 5.25 (4.95)   |
| Abdominal pain upper                     | 534                  |                             | 5.14 (4.71–5.61)       | 4.95 (1686.01) | 2.29 (2.16) | 4.92 (4.51)   |
| Abdominal discomfort                      | 525                  |                             | 5.46 (5.00–5.97)       | 5.26 (1813.06) | 2.37 (2.24) | 5.23 (4.79)   |
| Dry mouth                                | 521                  |                             | 14.18 (12.97–15.49)    | 13.59 (5965.45)| 3.70 (3.57) | 13.32 (12.19) |
| Abdominal pain                           | 396                  |                             | 3.44 (3.11–3.80)       | 3.36 (659.03)  | 1.73 (1.58) | 3.35 (3.03)   |
| Dyspepsia                                | 385                  |                             | 8.41 (7.59–9.31)       | 8.16 (2398.36) | 2.98 (2.83) | 8.07 (7.29)   |
| Stomatitis                               | 332                  |                             | 10.06 (9.01–11.23)     | 9.80 (2591.38) | 3.23 (3.07) | 9.67 (8.66)   |
| Abdominal distension                     | 309                  |                             | 5.98 (5.34–6.69)       | 5.85 (1234.99) | 2.51 (2.34) | 5.80 (5.18)   |
| Intestinal obstruction                   | 230                  |                             | 11.51 (10.09–13.13)    | 11.30 (2124.80) | 3.41 (3.21) | 11.12 (9.75)  |
| Flatulence                               | 216                  |                             | 7.74 (6.76–8.86)       | 7.61 (1228.92) | 2.86 (2.66) | 7.53 (6.58)   |
| Dysphagia                                | 169                  |                             | 3.55 (3.05–4.14)       | 3.52 (303.79)  | 1.78 (1.55) | 3.50 (3.01)   |
| Ascites                                  | 158                  |                             | 10.64 (9.08–12.46)     | 10.51 (1338.52)| 3.28 (3.05) | 10.35 (8.83)  |
| Retching                                 | 156                  |                             | 15.28 (13.03–17.93)    | 15.09 (2005.82)| 3.75 (3.52) | 14.76 (12.58) |
| Oral pain                                | 110                  |                             | 9.36 (7.75–11.31)      | 9.28 (801.80)  | 3.08 (2.80) | 9.16 (7.58)   |
| General disorders and administration site conditions |                      |                             |                        |                |              |               |
| Fatigue                                  | 3075                 |                             | 9.11 (8.75–9.50)       | 6.98 (16200.17) | 2.79 (2.73) | 6.92 (6.64)   |
| Anemia                                   | 1158                 |                             | 6.48 (6.10–6.89)       | 5.94 (4791.56) | 2.55 (2.46) | 5.85 (5.54)   |
| Malaise                                  | 670                  |                             | 2.69 (2.49–2.91)       | 2.60 (670.55)  | 1.37 (1.25) | 2.59 (2.40)   |
| Adverse drug reaction                    | 595                  |                             | 12.40 (11.41–13.48)    | 11.82 (5807.91)| 3.51 (3.39) | 11.62 (10.69) |
| Disease progression                      | 593                  |                             | 12.00 (11.04–13.04)    | 11.44 (5574.21)| 3.47 (3.34) | 11.25 (10.35) |
| Feeling abnormal *                       | 557                  |                             | 4.35 (3.99–4.74)       | 4.19 (1358.61) | 2.05 (1.92) | 4.17 (3.83)   |
| Peripheral swelling                      | 259                  |                             | 2.43 (2.15–2.75)       | 2.40 (213.07)  | 1.25 (1.07) | 2.40 (2.12)   |
| Drug intolerance                         | 228                  |                             | 3.49 (3.06–3.98)       | 3.44 (394.47)  | 1.75 (1.56) | 3.43 (3.00)   |
| Ill-defined disorder                     | 179                  |                             | 6.65 (5.73–7.71)       | 6.56 (836.56)  | 2.65 (2.43) | 6.50 (5.60)   |
| Illness                                  | 175                  |                             | 5.01 (4.31–5.82)       | 4.95 (548.93)  | 2.26 (2.04) | 4.92 (4.23)   |
| Unevaluable event                        | 131                  |                             | 3.08 (2.59–3.66)       | 3.06 (181.42)  | 1.58 (1.32) | 3.05 (2.57)   |
| Decreased activity                       | 116                  |                             | 21.91 (18.19–26.39)    | 21.70 (2214.14)| 4.15 (3.88) | 21.00 (17.43) |
| Infections and infestations              |                      |                             |                        |                |              |               |
| Urinary tract infection                  | 340                  |                             | 3.71 (3.33–4.13)       | 3.63 (648.91)  | 1.84 (1.68) | 3.61 (3.24)   |
| Nasopharyngitis                          | 238                  |                             | 2.47 (2.17–2.81)       | 2.44 (202.96)  | 1.27 (1.08) | 2.43 (2.14)   |

Continued
| SOC | Preferred terms (PTs) | Niraparib cases reporting PT | ROR (95% two-sided CI) | PRR ($\chi^2$) | IC (IC025) | EBGM (EBGM05) |
|-----|----------------------|-------------------------------|------------------------|----------------|-------------|----------------|
| Investigations | Platelet count decreased | 2330 | 54.14 (51.67–56.72) | 45.56 (90,943.01) | 5.32 (5.26) | 40.75 (38.90) |
| | Blood pressure increased | 1346 | 18.25 (17.24–19.33) | 16.27 (18,932.10) | 3.97 (3.89) | 15.88 (14.99) |
| | Carbohydrate antigen 125 increased | 1331 | 1067.22 (977.68–1164.95) | 945.93 (496,419.82) | 8.19 (8.09) | 374.25 (342.85) |
| | Haemoglobin decreased | 1051 | 22.78 (21.36–24.29) | 20.82 (19,269.58) | 4.31 (4.21) | 20.17 (18.92) |
| | White blood cell count decreased | 823 | 14.70 (13.68–15.79) | 13.73 (9554.34) | 3.73 (3.62) | 13.46 (12.53) |
| | Neutrophil count decreased | 812 | 9.13 (7.89–10.57) | 9.00 (1299.47) | 3.08 (2.87) | 8.89 (7.68) |
| | Tumour marker increased | 133 | 62.72 (53.82–73.10) | 61.76 (9947.24) | 5.43 (5.20) | 56.24 (48.25) |
| | Blood potassium decreased | 167 | 11.20 (9.60–13.07) | 11.06 (1502.89) | 3.35 (3.13) | 10.88 (9.33) |
| | Blood magnesium decreased | 158 | 35.06 (29.84–41.20) | 34.60 (4884.26) | 4.76 (4.53) | 32.82 (27.93) |
| | Metabolism and nutrition disorders | Decreased appetite | 1176 | 10.19 (9.59–10.83) | 9.27 (8639.33) | 3.18 (3.09) | 9.14 (8.61) |
| | Dehydration | 393 | 6.33 (5.73–7.01) | 6.16 (1689.59) | 2.59 (2.44) | 6.1 (5.52) |
| | Arthralgia | 678 | 3.31 (3.07–3.58) | 3.18 (1026.84) | 1.66 (1.54) | 3.17 (2.93) |
| | Back pain | 490 | 4.09 (3.74–4.48) | 3.96 (1089.14) | 1.97 (1.83) | 3.94 (3.60) |
| | Myalgia | 292 | 3.39 (3.02–3.81) | 3.33 (477.10) | 1.71 (1.54) | 3.32 (2.95) |
| | Muscle spasms | 276 | 2.90 (2.58–3.27) | 2.86 (334.64) | 1.50 (1.32) | 2.85 (2.53) |
| | Muscle weakness | 167 | 2.98 (2.56–3.48) | 2.96 (216.03) | 1.53 (1.31) | 2.95 (2.53) |
| | Bone pain | 160 | 5.08 (4.34–5.94) | 5.02 (512.91) | 2.28 (2.04) | 4.99 (4.27) |
| | Arthritis | 122 | 2.96 (2.48–3.54) | 2.94 (156.24) | 1.52 (1.25) | 2.93 (2.45) |
| | Headache | 1318 | 4.19 (3.96–4.44) | 3.83 (2823.61) | 1.93 (1.84) | 3.81 (3.60) |
| | Dizziness | 905 | 3.75 (3.50–4.01) | 3.54 (1673.98) | 1.81 (1.71) | 3.52 (3.29) |
| | Neuropathy peripheral * | 649 | 12.93 (11.94–14.01) | 12.27 (6166.89) | 3.56 (3.45) | 12.05 (11.12) |
| | Hypoaesthesia | 235 | 3.16 (2.77–3.59) | 3.11 (337.60) | 1.61 (1.42) | 3.10 (2.73) |
| | Balance disorder * | 220 | 4.83 (4.23–5.53) | 4.76 (651.15) | 2.21 (2.01) | 4.73 (4.14) |
| | Tremor | 215 | 2.54 (2.22–2.91) | 2.51 (196.32) | 1.31 (1.11) | 2.51 (2.19) |
| | Delirium | 213 | 7.00 (6.11–8.02) | 6.89 (1063.97) | 2.73 (2.53) | 6.83 (5.96) |
| | Memory impairment * | 205 | 2.58 (2.25–2.96) | 2.55 (193.94) | 1.33 (1.13) | 2.55 (2.22) |
| | Taste disorder | 174 | 16.26 (13.97–18.92) | 16.03 (2392.61) | 3.84 (3.62) | 15.65 (13.45) |
| Psychiatric disorders | Insomnia | 1722 | 14.50 (13.77–15.27) | 12.51 (18,093.9) | 3.61 (3.53) | 12.28 (11.67) |
| | Anxiety | 554 | 3.59 (3.30–3.91) | 3.47 (981.34) | 1.78 (1.65) | 3.45 (3.17) |
| | Emotional distress * | 429 | 5.15 (4.68–5.68) | 5.00 (1372.11) | 2.30 (2.15) | 4.97 (4.51) |
| | Sleep disorder | 330 | 8.94 (8.01–9.98) | 8.72 (2230.66) | 3.07 (2.91) | 8.61 (7.71) |
| | Stress | 171 | 4.56 (3.92–5.31) | 4.51 (465.39) | 2.13 (1.90) | 4.49 (3.85) |
| | Nervousness | 125 | 4.89 (4.10–5.84) | 4.85 (379.83) | 2.21 (1.95) | 4.82 (4.04) |
| | Middle insomnia | 110 | 13.52 (11.18–16.35) | 13.40 (1236.51) | 3.55 (3.27) | 13.14 (10.87) |
| | Renal and urinary disorders | Renal impairment | 320 | 6.65 (5.95–7.44) | 6.50 (479.45) | 2.66 (2.49) | 6.44 (5.76) |
| | Renal disorder | 100 | 3.78 (3.10–4.60) | 3.75 (201.25) | 1.85 (1.56) | 3.74 (3.07) |

Continued
mal (PT: 10016322), blood potassium decreased (PT: 10005724), heart rate increased (PT: 10019303), balance disorder (PT: 10049848), memory impairment (PT: 10027175). However, rash, diarrhea, intestinal perforation, peripheral edema, bronchitis, conjunctivitis, gamma-glutamyl transferase increased, albumin decreased, blood alkaline phosphatase increased, depression and cardiac arrest which were listed in drug label, did not meet the criteria for at least one of the four algorithms.

Onset time of events. The onset times of niraparib-associated AEs were collected from the database. Excluding unreported or unknown onset time reports, a total of 4323 AEs (36.95%, data available in 4323/11,701) reported onset time and the median onset time was 18 days (interquartile range [IQR] 14–48 days). As shown in Fig. 1, results indicated that the onsets of niraparib were variable, most of the cases occurred within the first 1 (n = 2720, 62.92%), 2 (n = 10.71%) and 3 months (n = 240, 5.55%) after niraparib initiation. Notably, AEs might still occur after 1 year of niraparib treatment with percentage of 5.22% as illustrated in our data.

### Table 3. Signal strength of reports of niraparib at the preferred term (PT) level in FAERS database. *Emerging findings of niraparib associated AEs from FAERS database. ROR reporting odds ratio; CI confidence interval; PRR proportional reporting ratio; \( \chi^2 \) chi-squared; IC information component; IC025 the lower limit of 95% CI of the IC; EBGM empirical Bayesian geometric mean; EBGM05 the lower limit of 95% CI of EBGM.

| SOC | Preferred terms (PTs) | Niraparib cases reporting PT | ROR (95% two-sided CI) | PRR \( (\chi^2) \) | IC (IC025) | EBGM (EBGM05) |
|-----|-----------------------|-------------------------------|------------------------|-----------------|----------|----------------|
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | 859 | 2.92 (2.73–3.13) | 2.78 (1001.66) | 1.47 (1.36) | 2.77 (2.59) |
| | Cough | 425 | 2.85 (2.58–3.14) | 2.78 (488.14) | 1.46 (1.32) | 2.77 (2.51) |
| | Oropharyngeal pain | 206 | 4.26 (3.71–4.89) | 4.20 (501.03) | 2.03 (1.83) | 4.18 (3.64) |
| | Dyspnoea exertional | 160 | 7.15 (6.11–8.37) | 7.07 (825.90) | 2.75 (2.51) | 7.00 (5.98) |
| | Epistaxis | 153 | 3.57 (3.04–4.19) | 3.54 (277.98) | 1.78 (1.55) | 3.52 (3.00) |
| | Rhinorrhea | 149 | 4.09 (3.48–4.81) | 4.05 (340.73) | 1.97 (1.73) | 4.03 (3.42) |
| | Pleural effusion | 113 | 3.61 (3.00–4.34) | 3.58 (209.74) | 1.79 (1.52) | 3.57 (2.96) |
| Skin and subcutaneous tissue disorders | Photosensitivity reaction | 204 | 23.58 (20.48–27.15) | 23.19 (4177.97) | 4.33 (4.13) | 22.39 (19.44) |
| | Hyperhidrosis | 167 | 2.59 (2.22–3.02) | 2.57 (160.02) | 1.33 (1.11) | 2.56 (2.20) |
| | Hypertension | 715 | 7.14 (6.62–7.71) | 6.77 (3509.00) | 2.73 (2.62) | 6.71 (6.21) |
| Vascular disorders | Hot flush | 219 | 5.98 (5.23–6.84) | 5.89 (882.89) | 2.51 (2.31) | 5.84 (5.11) |
| | Blood pressure fluctuation | 164 | 9.74 (8.34–11.38) | 9.62 (1248.94) | 3.16 (2.94) | 9.49 (8.12) |
| | Thrombosis | 112 | 2.61 (2.17–3.15) | 2.60 (109.78) | 1.34 (1.06) | 2.59 (2.15) |

Figure 1. Time to onset of niraparib-related AEs.
Discussion
This large real-world comparison of niraparib leveraged FAERS data and demonstrated that the most commonly reported and significant signals at SOC levels, likelihood of gastrointestinal disorders, blood and lymphatic system disorders, general disorders, administration site conditions, investigations, nervous system disorders, etc. In contrast, significant disproportionality of AEs in the skin and subcutaneous tissue disorders, renal and urinary disorders, cardiac disorders, infections and infestations are less common. It’s worth noting that, we did not find disproportionality reporting for endocrine systems, such as adrenal insufficiency, thyroid dysfunction, and hypophysis.

The AEs of niraparib occurred more commonly in females (78.55%) than in males (1.79%), due to the specific indications for ovarian and fallopian tube cancer. PARP inhibitors (PARPi) such as niraparib have been approved for different malignancies with genomic alternation in germline breast cancer susceptibility gene (BRCA) and DNA damage response (DDR) pathway genes. Studies have demonstrated that PARP inhibitor efficacy in BRCA mutated ovarian and breast cancer, prostate cancer, pancreatic cancer and small cell lung carcinoma (SCLC)14. In addition to the label indications, niraparib has great potential for the treatment of cholangiocarcinoma tumor15, prostate tumor16,17, breast cancer18,19 and lung cancer20. This study also illustrated a higher AEs proportion in elderly patients (33.54% > 50 years), which was consistent with the epidemiology of ovarian cancer. The risk of ovarian cancer increases in females with age21, although there was an overall decreasing trend of incidence and mortality of ovarian cancer over the past decade, a substantial increase in incidence was observed in younger females in some countries22. Furthermore, physicians may need to exercise additional caution when using niraparib in the elderly population, given the complex/various comorbidities that these patients typically experience.

The signal of niraparib in tumour marker increased, carbohydrate antigen 125 increased may be due to the failure of one prior systemic therapy, and patients may still have tumor metastasis and tumor progression when the efficacy of niraparib is imperfect. Moreover, owing to the characteristics of local invasion and distant metastasis of malignant tumors, it might be illogical to judge whether tumor metastasis and tumor progression are caused by niraparib only by ADR signals23.

Based on the disproportionality analysis, many organs or tissues can be involved, although some AEs reported much more commonly than others. Results demonstrated that the most commonly significant signals at SOC levels were general disorders, administration site conditions, investigations, gastrointestinal disorders, nervous system disorders, injury, poisoning and procedural complications. Among them, significant AEs mainly included anaemia, dizziness, abdominal pain, constipation, nausea, anaemia, blood magnesium decreased and blood pressure increased which were corresponding to that in the instruction and clinical safety data4,8,24. The signals of disproportionality reporting in FAERS showed a high risk in blood and lymphatic system. Findings from postmarketing studies suggest the risk may be significant. Studies have shown that haematological events were the most commonly occurring grade ≥ 3 AEs in patients with ovarian cancer for niraparib treatment24. Grade ≥ 3 AEs with an incidence ≥ 10% in niraparib recipients included anaemia (31.0% of niraparib females in some countries22. Furthermore, physicians may need to exercise additional caution when using niraparib.

The signal of niraparib in tumour marker increased, carbohydrate antigen 125 increased may be due to the failure of one prior systemic therapy, and patients may still have tumor metastasis and tumor progression when the efficacy of niraparib is imperfect. Moreover, owing to the characteristics of local invasion and distant metastasis of malignant tumors, it might be illogical to judge whether tumor metastasis and tumor progression are caused by niraparib only by ADR signals23.

Based on the disproportionality analysis, many organs or tissues can be involved, although some AEs reported much more commonly than others. Results demonstrated that the most commonly significant signals at SOC levels were general disorders, administration site conditions, investigations, gastrointestinal disorders, nervous system disorders, injury, poisoning and procedural complications. Among them, significant AEs mainly included anaemia, dizziness, abdominal pain, constipation, nausea, anaemia, blood magnesium decreased and blood pressure increased which were corresponding to that in the instruction and clinical safety data4,8,24. The signals of disproportionality reporting in FAERS showed a high risk in blood and lymphatic system. Findings from postmarketing studies suggest the risk may be significant. Studies have shown that haematological events were the most commonly occurring grade ≥ 3 AEs in patients with ovarian cancer for niraparib treatment24. Grade ≥ 3 AEs with an incidence ≥ 10% in niraparib recipients included anaemia (31.0% of niraparib recipients and 1.6% of placebo recipients), thrombocytopenia (28.7% and 0.4%), platelet count decreased (13.0% and 1.2%). The majority of niraparib treatment discontinuations were due to myelosuppressive events, including thrombocytopenia (4.3%), leukopenia (2.1%), anaemia (1.9%) and neutropenia (1.9%)25. Our results are in agreement with the studies regarding the disproportionately high reporting found for blood and lymphatic system disorders. Myelosuppression were the main reason for discontinuation but were relatively infrequent, and the niraparib package insert advises checking complete blood counts periodically.

There is a growing concern that patients treated with niraparib may experience an increased risk in blood and lymphatic system. Haematological reactions were managed with monitoring and dose reduction or interruption. Careful use of antiepileptate and anti-coagulants is recommended in patients receiving niraparib due to its increased risk of thrombocytopenia. It is important to note that niraparib does not currently have a ‘boxed warning’ for an increased risk of myelosuppression. Given the observed increased reporting risk for anemia, thrombocytopenia as well as neutropenia with niraparib found in the current study, additional analyses are warranted.

For cardiovascular events, such as hypertension, palpitations and tachycardia, the underlying mechanism of niraparib-induced cardiotoxicity remains unclear. Based on investigations in preclinical models, PARP inhibition appears to be limit or inhibit cardiovascular dysfunction25. According to the specification of ZEJULA (niraparib) capsules, niraparib caused effects on pulse rate and blood pressure, which may be related to pharmacological inhibition of the dopamine, norepinephrine, and serotonin transporter26. Besides, the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) recently issued a warning about the risk of severe hypertension and posterior reversible encephalopathy syndrome in niraparib.

Gastrointestinal events are frequent during niraparib treatment, including abdominal pain, nausea, constipation, and vomiting, of which nausea is the most common event. As we all know, gastrointestinal toxicity is a well-known side effect of PARP inhibitors which is mediated via off-target kinase inhibition. These types of AEs (e.g., nausea) are common for kinase inhibitors and often occurring early after treatment initiation. Patients should be prescribed antiemetics (e.g., ondansetron or prochlorperazine) to take as needed. A trial of scheduled antiemetics prior to each dose can be considered in patients with persistent emesis, while dose reductions can be considered in refractory cases.

It’s important to note that the neurological AEs associated with niraparib, which is the most common is insomnia. A study in Sweden showed that PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina therefore mediate circadian transcriptional plasticity27. The neurological AEs should be distinguished from other causes, such as central nervous system involvement and endocrine abnormalities.

It’s worth noting that we found disproportionality reporting for the psychiatric disorders, such as emotional distress, anxiety, stress, nervousness et al. About 50% of cancer patients have in fact been shown to have
psychiatric disorders as a consequence of cancer at some point during the cancer trajectory\textsuperscript{27}. Mood disorders are common in patients with female genital malignancy, so appropriate psychological intervention is necessary.

Unexpected and significant safety signals such as neuropathy peripheral, photosensitivity reaction, gastroesophageal reflux disease, blood potassium decreased, balance disorder, memory impairment, and emotional distress were detected in our analysis. A meta-analysis shows that PARP inhibition does not appear to reduce the risk of chemotherapy-induced peripheral neuropathy\textsuperscript{19}. Whether niraparib may lead to neuropathy remains an area in need of further investigation. The decrease in blood potassium may be associated with vomiting. At present, the mechanism of niraparib-induced balance disorder and memory impairment is not completely understood. The possible potential mechanism may be the unique pharmacology of niraparib including better blood–brain-barrier penetrance over other PARP inhibitors, which has been shown to induce intracranial response in animal models\textsuperscript{29}. In addition, we did not find relevant literature reports about other significant new signals, like photosensitivity reactions, gastroesophageal reflux, and emotional distress. Accordingly, further clinical studies are necessary to understand the pathogenesis of these adverse events.

Although the niraparib package insert and clinical case reports have indicated that it can cause rash, diarrhea, intestinal perforation, peripheral edema, bronchitis, conjunctivitis, gamma-glutamyl transferase increased, albumin decreased, blood alkaline phosphatase increased, depression and cardiac arrest in ovarian cancer cancer patients, the signal strength did not meet the criteria in our analysis. Results of this study indicated that the median onset time was 18 days, and most of the cases occurred within the first 1 (n = 2720, 62.92%), 2 (n = 10.71%) and 3 months (n = 240, 5.55%) after niraparib. Most of the AEs occurred with the first three months. Besides, the ENGOT-OV16/NOVA trial in the gBRCA mut and non-gBRCA mut cohorts, niraparib treatment resulted in a mean time with toxicity of 0.28 years and 0.10 years, respectively\textsuperscript{31}. These results suggested that we should be vigilant about the AEs associated with niraparib in the first month and early recognition of AEs caused by niraparib therapy is important due to these adverse drug effects can be life-threatening.

Although the current study showed a potentially insightful relationship between the use of niraparib and the odds of reporting AEs in the FAERS, it is not without limitations. In essence, voluntary reports are not restricted to health care professionals, and consumers are also candidates to report AEs. Whereas the medical expertise of the consumer is limited, unfortunately. As the FDA does not require a proof of causal relationship for submitted reports\textsuperscript{31}, partial correlate AEs maybe open to debate. Due to the lack of information in the FAERS database, it is difficult to control confounding factors such as age, comorbidities or other factors that may have an impact on health. Furthermore, with all the advantages brought by the data mining techniques conducted in this study, it should not be overlooked that this method does not address every problem of detecting and analyzing adverse drug reaction signals based on spontaneous reporting systems. Although data mining techniques cannot compensate for the inherent limitations of a spontaneous reporting system and substitute for expert review, it does have a place particularly where large volumes of data are involved\textsuperscript{32}. It is reassuring, however, that all signals identified in the previous system that went on to become frequently reported in the WHO database were also identified in the retrospective BCPNN analysis\textsuperscript{31}.

**Conclusion**

By analysis of FAERS data comprehensively and systematically, we identified risk tendencies and time to AEs onsets with niraparib. Unexpected and new significant AEs as neuropathy peripheral, photosensitivity reaction and gastroesophageal reflux disease might also occur. Common haemal, cardiovascular, and gastrointestinal AEs should be highly concerned. Clinicians should be aware of severe adverse reactions to tailor their agent choice and monitor their patients accordingly. We found multiple postmarketing safety signals which were similar to the clinical trials, as well as other reports that required further regulatory investigation to determine their significance. More research is needed in the future to explain the safety of niraparib for better application.

**Materials and methods**

**Data source and processing.** The FDA publishes FAERS files every quarter (i.e., four files each year). In our study, AE reports linked to niraparib submitted in the FAERS database from Q1 2017 (first approval period) to Q4 2021 (latest FAERS update) were extracted. Since the database is updated quarterly, it will inevitably duplicate the previous public reports, and the deduplication process is performed before statistical analysis in our study. After processing the original FAERS dataset, we created a dataset caused by the reports of niraparib.

**Adverse events and drug detection.** AEs in FAERS reports are coded using the Medical Dictionary for Regulatory Activities (MedDRA) of Preferred Terms (PTs). All individual AEs reports of niraparib recorded in system organ class (SOC) and PT levels were identified to describe the toxicity spectrum. The drugs in the FAERS database can be arbitrarily reported. Code for drug’s reported role in event include primary suspect drug (PS), secondary suspect drug (SS), concomitant (C), and interacting (I). As a result, our target drugs were defined as generic name (niraparib) and trade name (Zejula) in the DRUG file, and choose the role_cod as PS.

**Data mining algorithm.** We performed a disproportional analysis to identify potential associations between niraparib and AEs. The disproportional analysis was considered to be an important analytical tool in pharmacovigilance, and four statistical procedures were applied: reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multivariate gamma Poisson shrinker (MGPS)\textsuperscript{33}. By using these methods, we can identify the drug-events\textsuperscript{33}, as well as compare the proportion of adverse events occurring between a specific study drug and all other drugs. Four algorithms were applied to quantify the signals of niraparib-associated AEs in our study, and the equations and
criteria were described as previously and shown in Supplementary Table S2. These algorithms’ extraction decision rules were used to detect signals and calculate scores to measure associations between drugs and AEs. When a methodological threshold was met, the signals could be detected in SOC level. Basically, the higher the score of the four parameters, the stronger disproportion appears to be. In our study, we also discovered AE signals that simultaneously met the four algorithm standards in PT level. The novelty/unexpected signals were defined as significant AEs which were not listed in the instructions/product label.

The time-to-onset of AEs were calculated by subtracting the start date of niraparib from the onset date of report. We removed the reports with input errors (EVENT_DT earlier than START_DT) and the inaccurate date entries. The median and interquartile ranges were used to describe the time-to-onset. All data processing and statistical analyses were performed using MYSQL 8.0, Navicat Premium 15, Microsoft EXCEL 2019 and the GraphPad Prism 8 (GraphPad Software, CA, USA).

Ethical approval. This article does not contain any studies with human participants or animals performed by any of the authors.

Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Received: 7 July 2022; Accepted: 4 November 2022
Published online: 29 November 2022

References
1. Jones, P. et al. Discovery of 2-[4-[(3S)-piperidin-3-yl] phenyl]-2H-indazole-7-carboxamide (MK-4827): A novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J. Med. Chem. 52, 7170–7185 (2009).
2. Lheureux, S., Braunstein, M. & Oza, A. M. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. Curr. Treat. Options Oncol. 20, 1409–1419 (2019).
3. Niraparib (ZEJULA)[EB/OL]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s012lbl.pdf. (2020-02-27)
4. Mirza, M. R. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154–2164 (2016).
5. Smith, M. & Pothuri, B. Appropriate selection of PARP inhibitors in ovarian cancer. Curr. Treat. Options Oncol. 23, 887–903 (2022).
6. González-Martín, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391–2402 (2019).
7. Mirza, M. R. et al. Niraparib plus bevazirumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVAYA-Nova2/ENGOT-ov24): A randomised, phase 2, superiority trial. Lancet Oncol. 20, 1409–1419 (2019).
8. Moore, K. N. et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 20, 636–648 (2019).
9. Wu, X. H. et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): A randomized, double-blind, placebo-controlled phase III trial. Ann. Oncol. 32, 512–521 (2021).
10. Niraparib maintenance therapy in platinum-sensitive recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. Gynecol. Oncol. 159, 442–448 (2020).
11. Lee, A. Niraparib: A review in first-line maintenance therapy in advanced ovarian cancer. Target Oncol. 16, 839–845 (2021).
12. Setyawati, J., Azimi, N., Strand, V., Yarur, A. & Fridman, M. Reporting of thromboembolic events with JAK inhibitors: Analysis of the FAERS database 2010–2019. Drug Saf. 44, 889–897 (2021).
13. Vogel, U. et al. Investigating overlap in signals from EVDAS, FAERS, and VigilBase. Drug Saf. 43, 351–362 (2020).
14. Slade, D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 34, 360–394 (2020).
15. Bezrukoove, V. et al. Niraparib suppresses cholangiocarcinoma tumor growth by inducing oxidative and replication stress. Cancers (Basel) 13, 4405 (2021).
16. Saad, F. et al. Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: Safety and pharmacokinetic results from a phase Ib study. Cancer Chemother. Pharmacol. 88, 25–37 (2021).
17. Smith, M. R. et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALA-HAD): A multicentre, open-label, phase 2 trial. Lancet Oncol. 23, 362–373 (2022).
18. Vinayak, S. et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 5, 1132–1140 (2019).
19. Turner, N. C. et al. Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: The EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. Clin. Cancer Res. 27, 5482–5491 (2021).
20. Ramalingam, S. S. et al. JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer. Cancer 128, 65–74 (2022).
21. Rosenberg, S. M. et al. BRCA1 and BRCA2 mutation testing in young women with breast cancer. JAMA Oncol. 2, 730–736 (2016).
22. Huang, J. et al. Worldwide burden, risk factors, and temporal trends of ovarian cancer: A global study. Cancers (Basel) 14, 2220 (2022).
23. Shu, Y., Ding, Y., Dai, B. & Zhang, Q. A real-world pharmacovigilance study of axitinib: Data mining of the public version of FDA adverse event reporting system. Expert Opin. Drug Saf. 21, 563–572 (2022).
24. Campo, J. M. et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA Trial. J. Clin. Oncol. 37, 2968–2973 (2019).
25. Henning, R. J., Bourgeois, M. & Harbison, R. D. Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors: Mechanisms of action and role in cardiovascular disorders. Cardiovasc. Toxicol. 18, 493–506 (2018).
26. Zhao, H. et al. PARP1—and CTCF-mediated interactions between active and repressed chromatin at the lamina promote oscillating transcription. Mol. Cell 59, 984–997 (2015).
27. Grassi, L. Psychiatric and psychosocial implications in cancer care: The agenda of psycho-oncology. Epidemiol. Psychiatr. Sci. 29, e89 (2020).
28. Balko, R., Hurley, R. & Jatoi, A. Poly (ADP-Ribose) polymerase inhibition for chemotherapy-induced peripheral neuropathy: A meta-analysis of placebo-controlled trials. J. Palliat. Med. 22, 977–980 (2019).
29. Zhang, J. et al. Phase I pharmacokinetic study of niraparib in Chinese patients with epithelial ovarian cancer. Oncologist 25, 19-e10 (2020).
30. Matulonis, U. A. et al. Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: A TWiST analysis of the ENGOT-OV16/NOVA trial. J. Clin. Oncol. 37, 3183–3191 (2019).

31. FDA FAERS public dashboard. Available at https://firis.fda.gov/extensions/fpwidgets/2e01da82-13fe-40e0-8c38-4da505737c36.html. Accessed April 12, 2021.

32. Shu, Y. et al. Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database. Cancer Med. https://doi.org/10.1002/cam4.3062 (2022).

33. Peng, L., Xiao, K., Ottaviani, S., Stebbing, J., & Wang, Y. A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for baricitinib. Expert Opin. Drug Saf. 19, 1505–1511 (2020).

34. Lindquist, M., Ståhl, M., Bate, A., Edwards, I. R. & Meyboom, R. H. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 23, 533–542 (2000).

35. Hauben, M., Zou, C., Bright, S. & Hung, E. More extreme duplication in the U.S. FDA FAERS database and a suggested check point for disproportionality analysis. Pharmacoeconom. Drug Saf. 30, 1140–1141 (2021).

36. Hu, Y. et al. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int. Immunopharmacol. 84, 106601 (2020).

37. Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10, 796–803 (2013).

Author contributions
M.G. and J.L. contributed to conception and study design. Y.S. and F.L. analyzed data, prepared all figures and Tables, and took responsibility for the collection, integrity and accuracy of the data. M.G. and G.C. wrote the main manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-23726-4.

Correspondence and requests for materials should be addressed to J.L. or F.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022